IAS 38 · Workpapers (Step 4 of 5)
Workpaper template
- Course
- Exercises
- Case studies
- Workpapers
- Exams
Intangible assets note
- Prepared by
- AI-assisted draft
- Reviewed by
- Not reviewed — human review required
- Status
- Published
Objective of the workpaper
Prepare the note by class: reconcile the opening and closing carrying amounts, check the required information (lives, methods, gross amounts and accumulated amounts, line items, indefinite-life assets) and calculate the total R&D expenditure recognised as an expense.
6 sections · 28 blocks · 3 calculations · 0 entries
- IAS 38 §118
- IAS 38 §122
- IAS 38 §126
Work this workpaper as a mission
Each case that uses this template opens in the mission workspace: data, analysis, calculation, entries, conclusion and review, with your progress saved.
1 instance from the cases: the calculations and entries below are run by the calculation engine.
- File and entity
- Professional file: year-end close of the intangible assets of a software publisher
- Case tasks documented here
- Calculate the capitalised cost of the Atlas module and the R&D expensed in the year.
- Reconcile the note on acquired licences and check the disclosures.
Inputs
InputsClass of intangible assets (internally generated or other)
TextRequired
Carrying amount at the beginning of the period
NumberRequired
200,000
Additions: separately acquired
Number
270,000
Additions: internally developed
Number
Additions: business combinations
Number
Revaluation increases
Number
Disposals (carrying amount)
Number
70,000
Amortisation for the period
Number
100,625
Impairment losses
Number
Revaluation decreases
Number
Transfers to assets held for sale (IFRS 5) (optional)
Number
Optional reconciliation line: carrying amount of assets classified as held for sale or included in a disposal group under IFRS 5 (para. 118).
Reversals of impairment losses (optional)
Number
Optional reconciliation line: reversals of impairment losses recognised in profit or loss during the period (para. 118).
Net exchange differences, positive (optional)
Number
Optional reconciliation line: positive net exchange differences, for example on translating the financial statements of a foreign operation (para. 118).
Net exchange differences, negative (optional)
Number
Optional reconciliation line: negative net exchange differences, entered as a positive amount and deducted (para. 118).
Other increases (optional)
Number
Optional reconciliation line: other increases in the carrying amount, to be described in the note (para. 118).
Other decreases (optional)
Number
Optional reconciliation line: other decreases in the carrying amount, entered as a positive amount and deducted, to be described in the note (para. 118).
Carrying amount at the end of the period (trial balance)
NumberRequired
299,375
Research expenditure expensed in the period
Number
50,000
Development expenditure expensed in the period
Number
30,000
Supporting evidence
EvidenceEvidence obtained and referenced (category, document reference)
EvidenceRequired
Reconciliation and R&D expensed
CalculationsIAS 38 §118IAS 38 §126
Closing carrying amount rebuilt
CalculationRequired
299,375
Carrying amount at the beginning of the period ; Carrying amount at the end of the period (trial balance) ; Additions: separately acquired ; Additions: internally developed ; Additions: business combinations ; Revaluation increases ; − Disposals (carrying amount) ; − Amortisation for the period ; − Impairment losses ; − Revaluation decreases ; − Transfers to assets held for sale (IFRS 5) (optional) ; Reversals of impairment losses (optional) ; Net exchange differences, positive (optional) ; − Net exchange differences, negative (optional) ; Other increases (optional) ; − Other decreases (optional)
Difference with the trial balance (must be nil)
CalculationRequired
0
Carrying amount at the beginning of the period ; Carrying amount at the end of the period (trial balance) ; Additions: separately acquired ; Additions: internally developed ; Additions: business combinations ; Revaluation increases ; − Disposals (carrying amount) ; − Amortisation for the period ; − Impairment losses ; − Revaluation decreases ; − Transfers to assets held for sale (IFRS 5) (optional) ; Reversals of impairment losses (optional) ; Net exchange differences, positive (optional) ; − Net exchange differences, negative (optional) ; Other increases (optional) ; − Other decreases (optional)
Total R&D expenditure expensed to disclose
Calculation
80,000
Research expenditure expensed in the period ; Development expenditure expensed in the period
Disclosure checklist
DisclosureIAS 38 §118IAS 38 §122IAS 38 §126
Information by class
ChecklistRequired
- Distinction between internally generated and other assets
- Finite or indefinite useful lives; useful lives or amortisation rates
- Amortisation methods for finite-life assets
- Gross amount and accumulated amortisation and impairment at the beginning and end
- Line items of the statement of comprehensive income that include amortisation
- Reconciliation of carrying amounts (movements by nature)
Indefinite-life assets
Checklist
- Carrying amount
- Reasons and significant factors supporting the indefinite life
Research and development
Checklist
- Total R&D expenditure recognised as an expense in the period
Conclusion
ConclusionConclusion on the completeness of the note
ConclusionRequired
Normative references
ReferencesParagraphs cited in this workpaper (verification status shown from the register)
References
Checks and financial statement impact
- The reconciliation agrees to the closing amountPass
- Assets
- 0
- Liabilities
- 0
- Profit or loss
- 0
- OCI
- 0
- Equity
- 0
Inputs
InputsClass of intangible assets (internally generated or other)
TextRequired
Carrying amount at the beginning of the period
NumberRequired
Additions: separately acquired
Number
Additions: internally developed
Number
Additions: business combinations
Number
Revaluation increases
Number
Disposals (carrying amount)
Number
Amortisation for the period
Number
Impairment losses
Number
Revaluation decreases
Number
Transfers to assets held for sale (IFRS 5) (optional)
Number
Optional reconciliation line: carrying amount of assets classified as held for sale or included in a disposal group under IFRS 5 (para. 118).
Reversals of impairment losses (optional)
Number
Optional reconciliation line: reversals of impairment losses recognised in profit or loss during the period (para. 118).
Net exchange differences, positive (optional)
Number
Optional reconciliation line: positive net exchange differences, for example on translating the financial statements of a foreign operation (para. 118).
Net exchange differences, negative (optional)
Number
Optional reconciliation line: negative net exchange differences, entered as a positive amount and deducted (para. 118).
Other increases (optional)
Number
Optional reconciliation line: other increases in the carrying amount, to be described in the note (para. 118).
Other decreases (optional)
Number
Optional reconciliation line: other decreases in the carrying amount, entered as a positive amount and deducted, to be described in the note (para. 118).
Carrying amount at the end of the period (trial balance)
NumberRequired
Research expenditure expensed in the period
Number
Development expenditure expensed in the period
Number
Supporting evidence
EvidenceEvidence obtained and referenced (category, document reference)
EvidenceRequired
Reconciliation and R&D expensed
CalculationsIAS 38 §118IAS 38 §126
Closing carrying amount rebuilt
CalculationRequired
Carrying amount at the beginning of the period ; Carrying amount at the end of the period (trial balance) ; Additions: separately acquired ; Additions: internally developed ; Additions: business combinations ; Revaluation increases ; − Disposals (carrying amount) ; − Amortisation for the period ; − Impairment losses ; − Revaluation decreases ; − Transfers to assets held for sale (IFRS 5) (optional) ; Reversals of impairment losses (optional) ; Net exchange differences, positive (optional) ; − Net exchange differences, negative (optional) ; Other increases (optional) ; − Other decreases (optional)
Difference with the trial balance (must be nil)
CalculationRequired
Carrying amount at the beginning of the period ; Carrying amount at the end of the period (trial balance) ; Additions: separately acquired ; Additions: internally developed ; Additions: business combinations ; Revaluation increases ; − Disposals (carrying amount) ; − Amortisation for the period ; − Impairment losses ; − Revaluation decreases ; − Transfers to assets held for sale (IFRS 5) (optional) ; Reversals of impairment losses (optional) ; Net exchange differences, positive (optional) ; − Net exchange differences, negative (optional) ; Other increases (optional) ; − Other decreases (optional)
Total R&D expenditure expensed to disclose
Calculation
Research expenditure expensed in the period ; Development expenditure expensed in the period
Disclosure checklist
DisclosureIAS 38 §118IAS 38 §122IAS 38 §126
Information by class
ChecklistRequired
- Distinction between internally generated and other assets
- Finite or indefinite useful lives; useful lives or amortisation rates
- Amortisation methods for finite-life assets
- Gross amount and accumulated amortisation and impairment at the beginning and end
- Line items of the statement of comprehensive income that include amortisation
- Reconciliation of carrying amounts (movements by nature)
Indefinite-life assets
Checklist
- Carrying amount
- Reasons and significant factors supporting the indefinite life
Research and development
Checklist
- Total R&D expenditure recognised as an expense in the period
Conclusion
ConclusionConclusion on the completeness of the note
ConclusionRequired
Normative references
ReferencesParagraphs cited in this workpaper (verification status shown from the register)
References